Startups
Our vision is a world in which neurological and psychiatric conditions are promptly and accurately diagnosed. Our mission is to use artificial intelligence to improve the speed and accuracy of clinical neuropsychological assessments. Neuropsychologists still widely use paper-pencil tests to assess cognitive functions, in order to diagnose a wide range of neurological and psychiatric conditions, such as dementia or ADHD. Such tests require substantial time and efforts to score. With neurodAIgnostics, neuropsychologists no longer spend annoying hours on scoring tests: our solutions provide robust scores in seconds, with minimal changes to current workflows. The prevalence of neurological and psychiatric conditions is growing. Do you share our excitement for making it easier for neuropsychologists to provide quality care to an increasing volume of patients? Let’s connect! Email us here: [email protected]
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 11, 2026 | Nine start-ups selected for the Digital Health Accelerator | Each of the selected ventures is developing solutions with the potential to fundamentally reshape how healthcare is delivered and experienced. Through the accelerator, they will gain access to a wide network of mentors, industry leaders, a... |
| Apr 8, 2026 | Swiss startups appoint new CEOs and senior hires across biotech, AI and proptech | Anaveon, a pre-clinical biotechnology company developing immune-modulating therapies for autoimmune and inflammatory disorders, has appointed Thaminda Ramanayake as Chief Executive Officer. Ramanayake succeeds Andreas Katopodis, who led th... |
| Oct 3, 2025 | Deeptech startups impress juries across Switzerland | Cradle and Oxyle have been name Norrsken VC’s Impact/100, an annual ranking by the Norrsken Foundation, which recognizes the 100 most promising impact startups from all over the world. Cradle Bio uses generative AI to help scientists desig... |
Reviews 0
FAQ about NeurodAIgnostics (Zurich, 2025)
What has the press written about NeurodAIgnostics (Zurich, 2025)?
Parsers VC has collected 4 articles mentioning NeurodAIgnostics (Zurich, 2025), among them “Nine start-ups selected for the Digital Health Accelerator” (May 11, 2026) and “Swiss startups appoint new CEOs and senior hires across biotech, AI and proptech” (Apr 8, 2026).
Is NeurodAIgnostics (Zurich, 2025) still active?
Yes, NeurodAIgnostics (Zurich, 2025) is active; its latest activity on Parsers VC dates from Jun 24, 2026.